Johnson & Johnson Completes Proteologix Acquisition, Gains Bispecific Antibody Assets June 28, 2024 AutoBot News 0 Johnson & Johnson gets two bispecific antibodies in early phase development for immune-mediated diseases through its Proteologix acquisition.